{"pmid":32297722,"title":"Consensus statement on the use of clozapine during the COVID-19 pandemic.","text":["Consensus statement on the use of clozapine during the COVID-19 pandemic.","J Psychiatry Neurosci","Siskind, Dan","Honer, William G","Clark, Scott","Correll, Christoph U","Hasan, Alkomiet","Howes, Oliver","Kane, John M","Kelly, Deanna L","Laitman, Robert","Lee, Jimmy","MacCabe, James H","Myles, Nick","Nielsen, Jimmi","Schulte, Peter F","Taylor, David","Verdoux, Helene","Wheeler, Amanda","Freudenreich, Oliver","32297722"],"journal":"J Psychiatry Neurosci","authors":["Siskind, Dan","Honer, William G","Clark, Scott","Correll, Christoph U","Hasan, Alkomiet","Howes, Oliver","Kane, John M","Kelly, Deanna L","Laitman, Robert","Lee, Jimmy","MacCabe, James H","Myles, Nick","Nielsen, Jimmi","Schulte, Peter F","Taylor, David","Verdoux, Helene","Wheeler, Amanda","Freudenreich, Oliver"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297722","week":"202016|Apr 13 - Apr 19","doi":"10.1503/jpn.200061","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664266651209564160,"score":8.233237,"similar":[{"pmid":32242646,"title":"Consensus statement on the use of clozapine during the COVID-19 pandemic","text":["Consensus statement on the use of clozapine during the COVID-19 pandemic","J Psychiatry Neurosci","Siskind, Dan","Honer, William G.","Clark, Scott","Correll, Christoph U.","Hasan, Alkomiet","Howes, Oliver","Kane, John M.","Kelly, Deanna L.","Laitman, Robert","Lee, Jimmy","MacCabe, James H.","Myles, Nick","Nielsen, Jimmi","Schulte, Peter F.","Taylor, David","Verdoux, Helene","Wheeler, Amanda","Freudenreich, Oliver","32242646"],"journal":"J Psychiatry Neurosci","authors":["Siskind, Dan","Honer, William G.","Clark, Scott","Correll, Christoph U.","Hasan, Alkomiet","Howes, Oliver","Kane, John M.","Kelly, Deanna L.","Laitman, Robert","Lee, Jimmy","MacCabe, James H.","Myles, Nick","Nielsen, Jimmi","Schulte, Peter F.","Taylor, David","Verdoux, Helene","Wheeler, Amanda","Freudenreich, Oliver"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32242646","week":"202014|Mar 30 - Apr 05","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Clozapine"],"_version_":1663352135771750401,"score":133.25748},{"pmid":32289791,"title":"A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.","text":["A Rational Use of Clozapine Based on Adverse Drug Reactions, Pharmacokinetics, and Clinical Pharmacopsychology.","Using Richardson and Davidson's model and the sciences of pharmacokinetics and clinical pharmacopsychology, this article reviewed the: (1) poor life expectancy associated with treatment-resistant schizophrenia (TRS), which may be improved in patients who adhere to clozapine; (2) findings that clozapine is the best treatment for TRS (according to efficacy, effectiveness and well-being); and (3) potential for clozapine to cause vulnerabilities, including potentially lethal adverse drug reactions such as agranulocytosis, pneumonia, and myocarditis. Rational use requires: (1) modification of the clozapine package insert worldwide to include lower doses for Asians and to avoid the lethality associated with pneumonia, (2) the use of clozapine levels for personalizing dosing, and (3) the use of slow and personalized titration. This may make clozapine as safe as possible and contribute to increased life expectancy and well-being. In the absence of data on COVID-19 in clozapine patients, clozapine possibly impairs immunological mechanisms and may increase pneumonia risk in infected patients. Psychiatrists should call their clozapine patients and families and explain to them that if the patient develops fever or flu-like symptoms, the psychiatrist should be called and should consider halving the clozapine dose. If the patient is hospitalized with pneumonia, the treating physician needs to assess for symptoms of clozapine intoxication since halving the dose may not be enough for all patients; consider decreasing it to one-third or even stopping it. Once the signs of inflammation and fever have disappeared, the clozapine dose can be slowly increased to the prior dosage level.","Psychother Psychosom","de Leon, Jose","Ruan, Can-Jun","Schoretsanitis, Georgios","De Las Cuevas, Carlos","32289791"],"abstract":["Using Richardson and Davidson's model and the sciences of pharmacokinetics and clinical pharmacopsychology, this article reviewed the: (1) poor life expectancy associated with treatment-resistant schizophrenia (TRS), which may be improved in patients who adhere to clozapine; (2) findings that clozapine is the best treatment for TRS (according to efficacy, effectiveness and well-being); and (3) potential for clozapine to cause vulnerabilities, including potentially lethal adverse drug reactions such as agranulocytosis, pneumonia, and myocarditis. Rational use requires: (1) modification of the clozapine package insert worldwide to include lower doses for Asians and to avoid the lethality associated with pneumonia, (2) the use of clozapine levels for personalizing dosing, and (3) the use of slow and personalized titration. This may make clozapine as safe as possible and contribute to increased life expectancy and well-being. In the absence of data on COVID-19 in clozapine patients, clozapine possibly impairs immunological mechanisms and may increase pneumonia risk in infected patients. Psychiatrists should call their clozapine patients and families and explain to them that if the patient develops fever or flu-like symptoms, the psychiatrist should be called and should consider halving the clozapine dose. If the patient is hospitalized with pneumonia, the treating physician needs to assess for symptoms of clozapine intoxication since halving the dose may not be enough for all patients; consider decreasing it to one-third or even stopping it. Once the signs of inflammation and fever have disappeared, the clozapine dose can be slowly increased to the prior dosage level."],"journal":"Psychother Psychosom","authors":["de Leon, Jose","Ruan, Can-Jun","Schoretsanitis, Georgios","De Las Cuevas, Carlos"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32289791","week":"202016|Apr 13 - Apr 19","doi":"10.1159/000507638","keywords":["Asian continental ancestry group/genetics","COVID-19","Clozapine, blood","Clozapine/adverse effects","Clozapine/metabolism","Clozapine/toxicity","Drug labeling","Infection","Inflammation","Mortality/drug effects"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Asians"],"_version_":1664071627245092864,"score":66.58246},{"pmid":32242182,"title":"A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).","text":["A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).","There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes. We reviewed the available evidence, and have not found this to be the case. We recommend that patients on such medications should continue on them unless there is a clinical indication to stop their use.","N Z Med J","Talreja, Hari","Tan, Jasmine","Dawes, Matt","Supershad, Sharen","Rabindranath, Kannaiyan","Fisher, James","Valappil, Sajed","van der Merwe, Veronica","Wong, Lisa","van der Merwe, Walter","Paton, Julian","32242182"],"abstract":["There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes. We reviewed the available evidence, and have not found this to be the case. We recommend that patients on such medications should continue on them unless there is a clinical indication to stop their use."],"journal":"N Z Med J","authors":["Talreja, Hari","Tan, Jasmine","Dawes, Matt","Supershad, Sharen","Rabindranath, Kannaiyan","Fisher, James","Valappil, Sajed","van der Merwe, Veronica","Wong, Lisa","van der Merwe, Walter","Paton, Julian"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32242182","week":"202014|Mar 30 - Apr 05","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135759167488,"score":53.136734},{"pmid":32034899,"title":"[Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].","text":["[Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia].","Zhonghua Jie He He Hu Xi Za Zhi","Zhao, J P","Hu, Y","Du, R H","Chen, Z S","Jin, Y","Zhou, M","Zhang, J","Qu, J M","Cao, B","32034899"],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Zhao, J P","Hu, Y","Du, R H","Chen, Z S","Jin, Y","Zhou, M","Zhang, J","Qu, J M","Cao, B"],"date":"2020-02-09T11:00:00Z","year":2020,"_id":"32034899","week":"20206|Feb 03 - Feb 09","doi":"10.3760/cma.j.issn.1001-0939.2020.0007","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352134718980097,"score":50.447453},{"pmid":32267984,"title":"ISUOG Consensus Statement on rationalization of gynecological ultrasound services in context of SARS-CoV-2.","text":["ISUOG Consensus Statement on rationalization of gynecological ultrasound services in context of SARS-CoV-2.","Ultrasound Obstet Gynecol","Bourne, T","Leonardi, M","Kyriacou, C","Al-Memar, M","Landolfo, C","Cibula, D","Condous, G","Metzger, U","Fischerova, D","Timmerman, D","van den Bosch, T","32267984"],"journal":"Ultrasound Obstet Gynecol","authors":["Bourne, T","Leonardi, M","Kyriacou, C","Al-Memar, M","Landolfo, C","Cibula, D","Condous, G","Metzger, U","Fischerova, D","Timmerman, D","van den Bosch, T"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267984","week":"202015|Apr 06 - Apr 12","doi":"10.1002/uog.22047","source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"_version_":1663609715854147585,"score":50.145653}]}